Researchers turned to an alternative marker, CD22, in an effort to expand therapeutic targets. CD22-directed CAR-T cells showed promise, achieving complete remission in about 70% of patients who ...

Mabs directed against the cell surface antigens, CD19 and CD22 conjugated to deglycosylated ricin A chain (dgRTA) have been tested in patients with non-Hodgkin's lymphoma (NHL), but not in ...

CAR T-cell therapy showed encouraging efficacy and good safety in newly diagnosed Ph-positive ALL,” the researchers wrote.

Cargo Therapeutics experienced a significant setback as firi-cel™, a CD22 CAR-T therapy, did not replicate the efficacy and safety results seen in earlier studies for post CD19 LBCL treatment.

The CD22-directed CAR-T, which was being tested in the FIRCE-1 study as a treatment for patients with relapsed/refractory large B-cell lymphoma (LBCL), was halted in January, with CARGO saying it ...